Meropenem Kalceks (Meropenem)

Meropenem exerts its antibacterial effect by binding to penicillin‑binding proteins (PBPs) located on the bacterial cell wall. This inhibits the final transpeptidation step of peptidoglycan synthesis, weakening the cell wall and leading to osmotic lysis and bacterial death. Its broad spectrum includes many Gram‑negative, Gram‑positive and anaerobic organisms, making it a potent carbapenem.

The dosage of Meropenem Kalceks is determined individually by the prescribing clinician based on infection type, severity, patient weight, renal function and susceptibility data. Typical adult regimens range from 0.5 g to 2 g administered intravenously every 8 hours, but exact dosing must follow the prescriber’s order and local guidelines.

Safety data for meropenem in pregnancy are limited, and the drug is classified as pregnancy category unknown. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus. Likewise, it is excreted in breast milk; breastfeeding decisions should be made after consulting a healthcare professional.

To place an order, visit the product page on gnhindia.com, enter the required quantity and submit the enquiry form. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain handling if needed—and assists with any required import documentation.

Meropenem shares the broad‑spectrum activity of the carbapenem class, similar to imipenem‑cilastatin and ertapenem, but it offers a slightly higher stability against many β‑lactamases and a lower propensity for inducing seizures. Its dosing flexibility (every 8 hours) and renal‑adjusted regimens make it a preferred option for severe nosocomial infections when susceptibility testing supports its use.

Meropenem Kalceks must be stored refrigerated at 2 °C to 8 °C, protected from light, and kept in its original container to maintain potency. Do not freeze the solution; if reconstituted, use within the time frame specified in the product labeling and discard any unused portion after the recommended period.

Meropenem Kalceks is supplied as a sterile powder for injection that is reconstituted with a compatible diluent and administered intravenously over 15–30 minutes. Infusion rates may be adjusted for patients with renal impairment or at risk of seizures. Administration should be performed by qualified healthcare personnel in a clinical setting.

The most critical adverse events to monitor include seizures, especially in patients with renal dysfunction or pre‑existing CNS disease, severe hypersensitivity reactions such as anaphylaxis, and Clostridioides difficile‑associated colitis, which can be life‑threatening. Prompt recognition and discontinuation of therapy, along with appropriate medical management, are essential.

Meropenem is contraindicated in individuals with a documented hypersensitivity to meropenem, other carbapenems, or any β‑lactam antibiotics. Caution is also advised for patients with a history of seizures, severe renal impairment not appropriately dose‑adjusted, and those receiving valproic acid without alternative seizure control measures. Clinical judgment should guide therapy decisions.